{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:41:20Z","timestamp":1775688080833,"version":"3.50.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"suppl_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,15]]},"DOI":"10.1093\/cid\/cit266","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T23:20:11Z","timestamp":1374708011000},"page":"S111-S117","source":"Crossref","is-referenced-by-count":36,"title":["Management of Mental Health Problems Prior to and During Treatment of Hepatitis C Virus Infection in Patients With Drug Addiction"],"prefix":"10.1093","volume":"57","author":[{"given":"Martin","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crisanto","family":"Diez-Quevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,8,15]]},"reference":[{"key":"key\n\t\t\t\t20171014000255_CIT266C1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/gast.2002.34750","article-title":"Psychiatric disorders among veterans with hepatitis C infection","volume":"123","author":"el-Serag","year":"2002","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171014000255_CIT266C2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2012.07.037","article-title":"Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement","volume":"57","author":"Schaefer","year":"2012","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171014000255_CIT266C3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2893.2009.01080.x","article-title":"Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents","volume":"16","author":"Grebely","year":"2009","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20171014000255_CIT266C4","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s10620-012-2141-4","article-title":"Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health\/substance abuse issues","volume":"57","author":"Bonner","year":"2012","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20171014000255_CIT266C5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014000255_CIT266C6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"issue":"suppl 3","key":"key\n\t\t\t\t20171014000255_CIT266C7","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/01.aids.0000192065.09281.01","article-title":"HIV, hepatitis C and HIV\/hepatitis C virus co-infection in vulnerable populations","volume":"19","author":"Backus","year":"2005","journal-title":"AIDS"},{"issue":"suppl 3","key":"key\n\t\t\t\t20171014000255_CIT266C8","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1097\/01.aids.0000192072.80572.43","article-title":"The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects","volume":"19","author":"Clifford","year":"2005","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171014000255_CIT266C9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1360-0443.2009.02509.x","article-title":"Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy","volume":"104","author":"Schafer","year":"2009","journal-title":"Addiction"},{"key":"key\n\t\t\t\t20171014000255_CIT266C10","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/S0149-2918(11)00021-X","article-title":"Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies","volume":"32","author":"Zanini","year":"2010","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171014000255_CIT266C11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/j.1440-1746.2011.07035.x","article-title":"Effect of pegylated interferon-alpha-2a treatment on mental health during recent hepatitis C virus infection","volume":"27","author":"Alavi","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20171014000255_CIT266C12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2893.2010.01393.x","article-title":"Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update","volume":"18","author":"Sockalingam","year":"2011","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20171014000255_CIT266C13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0893-133X(01)00407-9","article-title":"Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions","volume":"26","author":"Capuron","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20171014000255_CIT266C14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-2005-837813","article-title":"Depression during therapy with interferon alpha\u2014how long should an antidepressant treatment last?","volume":"38","author":"Nickel","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"key\n\t\t\t\t20171014000255_CIT266C15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1360-0443.2010.03347.x","article-title":"Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy","volume":"106","author":"Sasadeusz","year":"2011","journal-title":"Addiction"},{"key":"key\n\t\t\t\t20171014000255_CIT266C16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4088\/JCP.v66n0106","article-title":"Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction","volume":"66","author":"Raison","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20171014000255_CIT266C17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1874473710801020177","article-title":"Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects","volume":"1","author":"Schaefer","year":"2008","journal-title":"Curr Drug Abuse Rev"},{"key":"key\n\t\t\t\t20171014000255_CIT266C18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1360-0443.2004.00821.x","article-title":"Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?","volume":"99","author":"Schaefer","year":"2004","journal-title":"Addiction"},{"issue":"suppl 5","key":"key\n\t\t\t\t20171014000255_CIT266C19","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1086\/427445","article-title":"Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users","volume":"40","author":"Strathdee","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014000255_CIT266C20","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/hep.21791","article-title":"Hepatitis C treatment in \u201cdifficult-to-treat\u201d psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects","volume":"46","author":"Schaefer","year":"2007","journal-title":"Hepatology,"},{"key":"key\n\t\t\t\t20171014000255_CIT266C21","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171014000255_CIT266C22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2008.09.009","article-title":"Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program","volume":"37","author":"Litwin","year":"2009","journal-title":"J Subst Abuse Treat"},{"key":"key\n\t\t\t\t20171014000255_CIT266C23","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1053\/j.gastro.2006.02.023","article-title":"Alcohol use and treatment of hepatitis C virus: results of a national multicenter study","volume":"130","author":"Anand","year":"2006","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171014000255_CIT266C24","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s10620-012-2142-3","article-title":"Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C","volume":"57","author":"Bonner","year":"2012","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20171014000255_CIT266C25","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.23699","article-title":"Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C","volume":"52","author":"Leutscher","year":"2010","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014000255_CIT266C26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003495-200666020-00003","article-title":"Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management","volume":"66","author":"Loftis","year":"2006","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171014000255_CIT266C27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.pharmthera.2011.01.014","article-title":"Immune system to brain signaling: neuropsychopharmacological implications","volume":"130","author":"Capuron","year":"2011","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t20171014000255_CIT266C28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gut.2007.131607","article-title":"Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study","volume":"57","author":"Kraus","year":"2008","journal-title":"Gut"},{"key":"key\n\t\t\t\t20171014000255_CIT266C29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/JCP.0b013e31825d9982","article-title":"Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review","volume":"32","author":"Baraldi","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20171014000255_CIT266C30","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.3748\/wjg.v13.i43.5736","article-title":"Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks","volume":"13","author":"Robaeys","year":"2007","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20171014000255_CIT266C31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1176\/appi.psy.45.1.29","article-title":"Plasma levels of citalopram in depressed patients with hepatitis C","volume":"45","author":"Gleason","year":"2004","journal-title":"Psychosomatics"},{"key":"key\n\t\t\t\t20171014000255_CIT266C32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014000255_CIT266C33","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4088\/JCP.09m05282blu","article-title":"Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial","volume":"72","author":"Diez-Quevedo","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20171014000255_CIT266C34","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1365-2036.2007.03316.x","article-title":"Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C","volume":"25","author":"Raison","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20171014000255_CIT266C35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0163-8343(03)00091-4","article-title":"Mirtazapine for the treatment of interferon-induced psychopathology","volume":"25","author":"Russo","year":"2003","journal-title":"Gen Hosp Psychiatry"},{"key":"key\n\t\t\t\t20171014000255_CIT266C36","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gut.2004.055251","article-title":"Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study","volume":"54","author":"Piche","year":"2005","journal-title":"Gut"},{"key":"key\n\t\t\t\t20171014000255_CIT266C37","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1176\/appi.psy.49.5.442","article-title":"Three cases of successful tryptophan add-on or monotherapy of hepatitis C and IFNalpha-associated mood disorders","volume":"49","author":"Schaefer","year":"2008","journal-title":"Psychosomatics"},{"key":"key\n\t\t\t\t20171014000255_CIT266C38","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1345\/aph.1D516","article-title":"Bupropion for treatment of interferon-induced depression","volume":"38","author":"Malek-Ahmadi","year":"2004","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20171014000255_CIT266C39","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s10620-006-9519-0","article-title":"Modafinil's use in combating interferon-induced fatigue","volume":"52","author":"Martin","year":"2007","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20171014000255_CIT266C40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/0269881104040230","article-title":"Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms","volume":"18","author":"Maddock","year":"2004","journal-title":"J Psychopharmacol"},{"key":"key\n\t\t\t\t20171014000255_CIT266C41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-157-2-201207170-00006","article-title":"Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial","volume":"157","author":"Schaefer","year":"2012","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171014000255_CIT266C42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MCG.0b013e3181d88af5","article-title":"A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin","volume":"44","author":"Neri","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"key\n\t\t\t\t20171014000255_CIT266C43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4172\/2155-6105.1000109","article-title":"Effect of CBT on depressive symptoms in methadone maintenance patients undergoing treatment for hepatitis C","volume":"2","author":"Ramsey","year":"2011","journal-title":"J Addict Res Ther"},{"key":"key\n\t\t\t\t20171014000255_CIT266C44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2893.2005.00554.x","article-title":"Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon induced depression","volume":"12","author":"Kraus","year":"2005","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20171014000255_CIT266C45","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s10620-006-9729-5","article-title":"Preventing relapse of major depression during interferon-alpha therapy for hepatitis C\u2014a pilot study","volume":"52","author":"Gleason","year":"2007","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20171014000255_CIT266C46","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2005.01.020","article-title":"Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C","volume":"42","author":"Schaefer","year":"2005","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171014000255_CIT266C47","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/j.1365-2036.2011.04867.x","article-title":"Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C","volume":"34","author":"de Knegt","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20171014000255_CIT266C48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jad.2007.01.007","article-title":"A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C","volume":"103","author":"Morasco","year":"2007","journal-title":"J Affect Disord"},{"key":"key\n\t\t\t\t20171014000255_CIT266C49","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0033-3182(10)70722-2","article-title":"Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial","volume":"51","author":"Morasco","year":"2010","journal-title":"Psychosomatics"},{"key":"key\n\t\t\t\t20171014000255_CIT266C50","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jsat.2010.02.002","article-title":"High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin","volume":"38","author":"Waizmann","year":"2010","journal-title":"J Subst Abuse Treat"},{"key":"key\n\t\t\t\t20171014000255_CIT266C51","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/j.1365-2036.2009.04123.x","article-title":"Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C","volume":"30","author":"Schmidt","year":"2009","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/57\/suppl_2\/S111\/20911688\/cit266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T04:03:09Z","timestamp":1507953789000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/57\/suppl_2\/S111\/395647\/Management-of-Mental-Health-Problems-Prior-to-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,15]]},"references-count":51,"journal-issue":{"issue":"suppl_2","published-online":{"date-parts":[[2013,8,15]]},"published-print":{"date-parts":[[2013,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cit266","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,8,15]]},"published":{"date-parts":[[2013,8,15]]}}}